Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

EASD 2020 September 21 - 25

Efficacy and safety of switching to insulin icodec, a once-weekly basal insulin, vs insulin glargine U100 in patients with T2D inadequately controlled on OADs and basal insulin

Harpreet S. Bajaj1; Joakim Isendahl2; Amoolya Gowda2; Karolina A. Stachlewska2; Julio Rosenstock3;
1LMC Diabetes & Endocrinology, Brampton, Ontario, Canada; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada; 2Novo Nordisk A/S, Bagsværd, Denmark; 3Dallas Diabetes Research Center at Medical City, Dallas, TX, USA;

References

1.

Hövelmann U et al. Diabetes 2020;69(Suppl 1):237-OR; 

2.

Nishimura E et al. Diabetes 2020;69(Suppl 1):236-OR.

HSB has received speaker’s fees from AstraZeneca, Eli Lilly, Janssen, Merck and Novo Nordisk, and research funding from Amgen, AstraZeneca, Boehringer Ingelheim, Ceapro, Eli Lilly, Gilead, Janssen, Kowa, Madrigal, Merck, Novo Nordisk, Sanofi and Tricida. JR has received research support from Eli Lilly, Genentech, GlaxoSmithKline, Intarcia, Janssen, Merck, Novo Nordisk, Oramed, Pfizer and Sanofi. JI, AG and KS are employees of Novo Nordisk. This study was funded by Novo Nordisk. Medical writing support was provided by Dr Nicolas Bertheleme of Oxford PharmaGenesis, Oxford, UK, with funding from Novo Nordisk. Presented at the European Association for the Study of Diabetes (EASD) Annual Meeting, virtual format, 21–25 September 2020.